BioSig Technologies, Inc. (OTCMKTS:BSGM) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement
Company) entered into an amendment agreement (the Amendment
Agreement) to amend (A) that certain Unit Purchase Agreement,
dated May 26, 2016, (the Purchase Agreement), to which, in a
closing held on June 1, 2016, the Company issued units at a price
of $1.75 per unit, with each unit consisting of (i) one share of
the Companys common stock, par value $0.001 per share (the Common
Stock), and (ii) a warrant to purchase one-half of one share of
Common Stock at an exercise price of $2.10 per share
(collectively the Warrants), and (B) the Warrants, to reduce each
of the purchase price per unit and the exercise price per share
for the outstanding Warrants to $1.50. All other terms of the
Purchase Agreement and the Warrants remain the same. As of the
Effective Date, Warrants to purchase 38,572 shares of common
stock were outstanding.
purport to be complete and is qualified in its entirety by
reference to the full text of the Amendment Agreement, which is
filed as Exhibit 10.1 to this Current Report and is incorporated
herein by reference.
above, the Company issued an aggregate of 12,858 shares of Common
Stock and Warrants to purchase 6,429 shares of Common Stock to
three purchasers signatories to the Purchase Agreement. Such
issuance of the shares of Common Stock and the Warrants was not
registered under the Securities Act of 1933, as amended (the
Securities Act), or the securities laws of any state, and was
issued in reliance on the exemption from registration under the
Securities Act provided by Section 4(a)(2) and Regulation D (Rule
506) under the Securities Act.
Item 1.01, which is incorporated herein by reference.
|
Exhibit Number
|
Description
|
|
|
10.1
|
Amendment Agreement, dated February 9, 2017
|
About BioSig Technologies, Inc. (OTCMKTS:BSGM)
BioSig Technologies, Inc. is a development-stage medical device company. The Company is developing a technology platform to manage noise and artifacts from cardiac recordings during electrophysiology studies and ablation. It is engaged in developing the Precise Uninterrupted Real-time evaluation of Electrograms (PURE) electro-pneumatic (EP) System. PURE EP System is a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes and displays electrocardiogram and electrograms required during electrophysiology studies and ablation procedures. The Company’s PURE EP System is designed to assist electrophysiologists with real-time evaluations of electrocardiograms and electrograms, and helps in making clinical decisions in real-time. It is also developing signal-processing tools, which will assist electrophysiologists in differentiating true signals from noise and provide guidance in identifying ablation targets within the PURE EP System.
BioSig Technologies, Inc. (OTCMKTS:BSGM) Recent Trading Information
BioSig Technologies, Inc. (OTCMKTS:BSGM) closed its last trading session up +0.04 at 1.60 with 163,146 shares trading hands.
